Relmada Therapeutics RLMD
NASDAQ RLMD
$3.77 +0.04 (+1.07%)
At close: Sep 30, 2026 · 4:00 PM EDT

Relmada Therapeutics (RLMD) EBIT Margin (2012 - 2013)

Updated

Relmada Therapeutics' EBIT Margin came in at -877.66% for FY2013, down 725.89 percentage points from -151.77% in FY2012.

Analysis

Relmada Therapeutics (RLMD) EBIT Margin (2012 - 2013) Analysis & Trends

  • Per Business Quant, earlier years put EBIT Margin at -151.77% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 28.21%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 37.86%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -3.52%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 32.97%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 20.57%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 34.95%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -133.21%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 37.40%
10 Relmada Therapeutics 402.15 Mn 402.15 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Nov 30, 2013 -776.97%
May 31, 2013 -3,073.34%
Feb 28, 2013 -176.73%
Nov 30, 2012 -419.73%
Aug 31, 2012 -569.57%
May 31, 2012 -620.25%
API Access

Relmada Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY